Published in J Virol on July 03, 2012
Hepatitis C virus infection: establishment of chronicity and liver disease progression. EXCLI J (2014) 0.90
Production and pathogenicity of hepatitis C virus core gene products. World J Gastroenterol (2014) 0.85
Influence of HIV and HCV on T cell antigen presentation and challenges in the development of vaccines. Front Microbiol (2014) 0.83
Giving CD4+ T cells the slip: viral interference with MHC class II-restricted antigen processing and presentation. Curr Opin Immunol (2016) 0.77
Influence of host resistance on viral adaptation: hepatitis C virus as a case study. Infect Drug Resist (2015) 0.75
Classification of chronic viral hepatitis: a need for reassessment. J Hepatol (1991) 5.23
Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol (2001) 2.76
Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology (2001) 2.49
Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol (1999) 2.44
Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol (2004) 2.27
Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood (2001) 2.26
Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proc Natl Acad Sci U S A (2002) 1.96
Generation of infectious hepatitis C virus in immortalized human hepatocytes. J Virol (2006) 1.86
Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection. J Infect Dis (2003) 1.59
Hepatitis C virus core protein impairs in vitro priming of specific T cell responses by dendritic cells and hepatocytes. J Hepatol (2007) 1.54
Dendritic cells. Adv Immunol (1999) 1.51
Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. Hepatology (1988) 1.37
Trans-activation of HLA-DR gene by hepatitis B virus X gene product. Proc Natl Acad Sci U S A (1990) 1.22
The level of viral antigen presented by hepatocytes influences CD8 T-cell function. J Virol (2007) 1.16
Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene. Virology (2001) 1.16
Viral inhibition of MHC class II antigen presentation. Trends Immunol (2003) 1.16
Regulation of hepatitis C virus replication by interferon regulatory factor 1. J Virol (2004) 1.16
MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes. Hepatology (2003) 1.15
Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo. J Immunol (2005) 1.15
Immunoelectron microscopic observations on the inflammatory infiltrates and HLA antigens in hepatitis B and non-A, non-B. Hepatology (1988) 1.14
Endosomal proteases in antigen presentation. Curr Opin Immunol (2005) 1.13
Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J Virol (2008) 1.11
Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virology (2006) 1.08
Human cathepsin S, but not cathepsin L, degrades efficiently MHC class II-associated invariant chain in nonprofessional APCs. Proc Natl Acad Sci U S A (2003) 1.06
Dendritic cell susceptibility to hepatitis C virus genotype 1 infection. J Med Virol (2002) 1.05
Transcriptional repression of C4 complement by hepatitis C virus proteins. J Virol (2011) 1.04
IFN regulatory factor-1 regulates IFN-gamma-dependent cathepsin S expression. J Immunol (2002) 1.03
Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence? Lancet Infect Dis (2005) 1.03
Surface expression of the invariant chain (CD74) is independent of concomitant expression of major histocompatibility complex class II antigens. Immunology (1995) 1.02
Hepatitis C virus differentially modulates activation of forkhead transcription factors and insulin-induced metabolic gene expression. J Virol (2010) 1.00
A role for STAT3 and cathepsin S in IL-10 down-regulation of IFN-gamma-induced MHC class II molecule on primary human blood macrophages. J Leukoc Biol (2010) 0.96
Hepatitis C virus core protein interacts with fibrinogen-beta and attenuates cytokine stimulated acute-phase response. Hepatology (2010) 0.95
Inhibition of intrahepatic gamma interferon production by hepatitis C virus nonstructural protein 5A in transgenic mice. J Virol (2009) 0.94
Defective T helper response of hepatocyte-stimulated CD4 T cells impairs antiviral CD8 response and viral clearance. Gastroenterology (2007) 0.94
Hepatitis C virus and ethanol alter antigen presentation in liver cells. World J Gastroenterol (2009) 0.94
Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes. J Virol (2006) 0.90
Upregulation of major histocompatibility complex class II antigens in hepatocytes in Doberman hepatitis. Vet Immunol Immunopathol (2003) 0.87
Association of Doberman hepatitis to canine major histocompatibility complex II. Tissue Antigens (2010) 0.85
Cathepsin S inhibitors as novel immunomodulators. Curr Opin Investig Drugs (2005) 0.85
Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments. Immunology (1999) 0.84
Class I and class II major histocompatibility complex antigens expression on human hepatocytes and hepatoma cells: an approach with high sensitivity and specificity. Cytometry (1997) 0.84
PU.1 regulates cathepsin S expression in professional APCs. J Immunol (2006) 0.83
Treatment of hepatitis C infection. Gastroenterol Clin North Am (2006) 0.83
Proteases, processing, and thymic selection. Science (1998) 0.80
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum. Crit Care Med (2009) 3.16
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology (2002) 2.68
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood (2005) 2.50
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc (2006) 2.43
Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med (2009) 2.23
Validation of a gene expression-based subclassification strategy for pediatric septic shock. Crit Care Med (2011) 2.20
Liver transplantation for hepatocellular carcinoma. Gastroenterology (2005) 2.15
Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med (2015) 2.09
Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology (2009) 2.07
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
The pediatric sepsis biomarker risk model. Crit Care (2012) 1.99
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Hepatitis C virus genotype 1a growth and induction of autophagy. J Virol (2007) 1.96
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology (2008) 1.92
Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol (2009) 1.91
A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol (2009) 1.86
Generation of infectious hepatitis C virus in immortalized human hepatocytes. J Virol (2006) 1.86
Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions. J Infect Dis (2005) 1.84
Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression. Hepatology (2013) 1.79
Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev (2009) 1.79
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73
Post-ICU admission fluid balance and pediatric septic shock outcomes: a risk-stratified analysis. Crit Care Med (2014) 1.72
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Human regulatory T cells induce T-lymphocyte senescence. Blood (2012) 1.70
Polyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infection. Infect Immun (2012) 1.69
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology (2008) 1.66
The influence of developmental age on the early transcriptomic response of children with septic shock. Mol Med (2011) 1.57
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology (2010) 1.52
ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol (2011) 1.50
Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol (2006) 1.49
The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to Child-Turcotte-Pugh classification in predicting outcome. Arch Surg (2005) 1.49
A Multibiomarker-Based Model for Estimating the Risk of Septic Acute Kidney Injury. Crit Care Med (2015) 1.49
Knockdown of autophagy enhances the innate immune response in hepatitis C virus-infected hepatocytes. Hepatology (2011) 1.47
Th-17, monokines, collagen type V, and primary graft dysfunction in lung transplantation. Am J Respir Crit Care Med (2008) 1.44
Diagnosis of hepatocellular carcinoma. HPB (Oxford) (2005) 1.43
Clinical decisions. Management of incidental hepatitis C virus infection. N Engl J Med (2009) 1.42
Therapeutic hypercapnia enhances the inflammatory response to endotoxin in the lung of spontaneously breathing rats. Crit Care Med (2011) 1.40
Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol (2007) 1.38
Quality Metrics in Neonatal and Pediatric Critical Care Transport: A National Delphi Project. Pediatr Crit Care Med (2015) 1.38
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol (2006) 1.38
Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer. J Immunol (2012) 1.38
Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med (2004) 1.36
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients: implications for a biomarker of hepatocellular carcinoma. PLoS One (2010) 1.34
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
Interleukin-27 is a novel candidate diagnostic biomarker for bacterial infection in critically ill children. Crit Care (2012) 1.31
Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis (2010) 1.30
Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. Clin Diagn Lab Immunol (2002) 1.29
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine (2010) 1.28
Hepatitis C virus NS5A protein impairs TNF-mediated hepatic apoptosis, but not by an anti-FAS antibody, in transgenic mice. Virology (2002) 1.26
Only a subset of phosphoantigen-responsive gamma9delta2 T cells mediate protective tuberculosis immunity. J Immunol (2008) 1.23
Oncogenic potential of hepatitis C virus proteins. Viruses (2010) 1.22
Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol (2011) 1.20
Corticosteroids are associated with repression of adaptive immunity gene programs in pediatric septic shock. Am J Respir Crit Care Med (2014) 1.20
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis (2006) 1.19
Hepatitis C virus core protein inhibits tumor necrosis factor alpha-mediated apoptosis by a protective effect involving cellular FLICE inhibitory protein. J Virol (2006) 1.19
Accumulation of B lymphocytes with a naive, resting phenotype in a subset of hepatitis C patients. J Immunol (2003) 1.19
Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice. Infect Immun (2002) 1.18
Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology (2002) 1.18
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology (2009) 1.18
Hepatitis C virus upregulates Beclin1 for induction of autophagy and activates mTOR signaling. J Virol (2012) 1.17
Identification of candidate serum biomarkers for severe septic shock-associated kidney injury via microarray. Crit Care (2011) 1.16
Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect. J Virol (2006) 1.16
Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A. J Virol (2012) 1.15
Identification of a small-molecule entry inhibitor for filoviruses. J Virol (2011) 1.14
Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol (2012) 1.14
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology (2006) 1.13
Hepatitis C virus infection induces the beta interferon signaling pathway in immortalized human hepatocytes. J Virol (2007) 1.12
Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol (2003) 1.12
Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine (2008) 1.11
Hepatitis C virus infection impairs IRF-7 translocation and Alpha interferon synthesis in immortalized human hepatocytes. J Virol (2010) 1.11
CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2. Infect Immun (2005) 1.11
Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J Virol (2008) 1.11